chlorpheniramine maleate; hydrocodone bitartrate; pseudoephedrine hydrochloride
Drug data last refreshed 13h ago · AI intelligence enriched 2w ago
ZUTRIPRO is an oral solution combining chlorpheniramine maleate (antihistamine), hydrocodone bitartrate (opioid antitussive), and pseudoephedrine hydrochloride (decongestant) for symptomatic relief of cough and upper respiratory congestion. This fixed-dose combination addresses multiple cold and flu symptoms in a single formulation. The mechanism relies on peripheral antihistamine activity, central cough suppression via mu-receptor agonism, and alpha-1 adrenergic nasal decongestant effects.
Product is at peak commercial maturity with moderate competitive pressure (30/100); sustained team investment likely but growth limited without indication expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
ZUTRIPRO roles center on defending and optimizing market share in a mature, competitive segment. Career opportunities emphasize commercial execution, payer negotiation, and regulatory compliance rather than innovation or clinical advancement.
Worked on ZUTRIPRO at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.